How can we realize the promise of personalized antidepressant medicines?
作者： Florian Holsboer
DOI: 10.1038/NRN2453
关键词:
摘要: Personalized medication that is based on pharmacogenetic data has long been expected to improve the efficacy of treatments for neurological and psychiatric disorders, including depression. However, complexity regulation gene transcription its interactions with environmental factors means straightforward translation individual genetic information into tailored treatment unlikely. Nevertheless, when from genomics, proteomics, metabolomics, neuroimaging neuroendocrinology are used in combination, they could lead development effective personalized antidepressant both genotypes biomarkers. This process will require many further steps collaboration between basic clinical neuroscience.
nature.com
sci-hub.se 参考文章(103)
Jeffrey B. Kraft, Eric J. Peters, Susan L. Slager, Greg D. Jenkins, Megan S. Reinalda, Patrick J. McGrath, Steven P. Hamilton, Analysis of Association Between the Serotonin Transporter and Antidepressant Response in a Large Clinical Sample Biological Psychiatry. ,vol. 61, pp. 734- 742 ,(2007) , 10.1016/J.BIOPSYCH.2006.07.017
Wayne C. Drevets, Joseph L. Price, Joseph R. Simpson, Richard D. Todd, Theodore Reich, Michael Vannier, Marcus E. Raichle, Subgenual prefrontal cortex abnormalities in mood disorders Nature. ,vol. 386, pp. 824- 827 ,(1997) , 10.1038/386824A0
R. D. Airan, L. A. Meltzer, M. Roy, Y. Gong, H. Chen, K. Deisseroth, High-speed imaging reveals neurophysiological links to behavior in an animal model of depression. Science. ,vol. 317, pp. 819- 823 ,(2007) , 10.1126/SCIENCE.1144400
Jinke Cheng, Xunlei Kang, Sui Zhang, Edward T.H. Yeh, SUMO-Specific Protease 1 Is Essential for Stabilization of HIF1α during Hypoxia Cell. ,vol. 131, pp. 584- 595 ,(2007) , 10.1016/J.CELL.2007.08.045
CJ Hong, TJ Chen, Y WY Yu, SJ Tsai, None, Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics Journal. ,vol. 6, pp. 27- 33 ,(2006) , 10.1038/SJ.TPJ.6500340
Nadia Tsankova, William Renthal, Arvind Kumar, Eric J. Nestler, Epigenetic regulation in psychiatric disorders Nature Reviews Neuroscience. ,vol. 8, pp. 355- 367 ,(2007) , 10.1038/NRN2132
Yutaro Suzuki, Kazushi Sawamura, Toshiyuki Someya, Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patients. Neuropsychopharmacology. ,vol. 31, pp. 825- 831 ,(2006) , 10.1038/SJ.NPP.1300919
Greer M. Murphy, Steven B. Hollander, Heidi E. Rodrigues, Charlotte Kremer, Alan F. Schatzberg, Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Archives of General Psychiatry. ,vol. 61, pp. 1163- 1169 ,(2004) , 10.1001/ARCHPSYC.61.11.1163
F Holsboer, The Corticosteroid Receptor Hypothesis of Depression Neuropsychopharmacology. ,vol. 23, pp. 477- 501 ,(2000) , 10.1016/S0893-133X(00)00159-7
J Mill, A Petronis, Molecular studies of major depressive disorder: the epigenetic perspective. Molecular Psychiatry. ,vol. 12, pp. 799- 814 ,(2007) , 10.1038/SJ.MP.4001992